Please wait while the formulary information is being retrieved.
FASENRA (BENRALIZUMAB)
- Eosinophilic asthma
30 mg/mL subcutaneous syringe
- Inject 1 milliliter (30 mg) by subcutaneous route every 8 weeks in the abdomen, thigh, or upper arm
Eosinophilic asthma
- Inject 1 milliliter (30 mg) by subcutaneous route every 4 weeks in the abdomen, thigh, or upper arm for 3 doses
- Inject 1 milliliter (30 mg) by subcutaneous route every 4 weeks in the abdomen, thigh, or upper arm for 3 doses then every 8 weeks
- Inject 1 milliliter (30 mg) by subcutaneous route every 8 weeks in the abdomen, thigh, or upper arm
- Inject 1 milliliter (30 mg) by subcutaneous route every 8 weeks in the abdomen, thigh, or upper arm (dose 4 and thereafter)
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Acutely deteriorating asthma
- Parasitic infection
Severe
Moderate
- None
FASENRA (BENRALIZUMAB)
- Eosinophilic asthma
- None
- Headache disorder
- Pharyngitis
More Frequent
Severe
Less Severe
- Hypersensitivity drug reaction
- Fever
- Injection site sequelae
- Skin rash
- Urticaria
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Adrenal cortical insufficiency
- Anaphylaxis
- Angioedema
- Appendicitis
- Atrial fibrillation
- Cholecystitis
- Endometrial polyps
- Exostosis
- Leukopenia
- Lymphadenopathy
- Ocular hemorrhage
- Ovarian cyst
Less Severe
- Abdominal distension
- Allergic dermatitis
- Arthralgias
- Arthritis
- Chest pain
- Chills
- Conjunctival hemorrhage
- Cough
- Dysmenorrhea
- Gingivitis
- Hematuria
- Myalgias
- Nasal turbinate hypertrophy
- Nervousness
- Neuralgia
- Panic disorder
- Pelvic pain
- Respiratory tract congestion
- Sensation of cold
- Sinusitis
- Sleep disorder
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Benralizumab
No safety and efficacy age < 12 years.
- 1 Day – 12 Years
- No safety and efficacy age < 12 years.
Benralizumab
- Severity Level:
2
- Additional Notes: Insufficient human data available
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Benralizumab
Insuff human data; human igg present in breastmilk
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insuff human data; human igg present in breastmilk |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Eosinophilic asthma | |
| J82 | Pulmonary eosinophilia, not elsewhere classified |
| 0-9 | A-Z |
|---|---|
| J82 | Pulmonary eosinophilia, not elsewhere classified |
Formulary Reference Tool